No Data
No Data
Affimed Announces Acceptance Of An Abstract On Preclinical Data Of Its Innate Cell Engager AFM28 At The EHA 2024 Congress
Treatment with AFM28 innate cell engager (ICE), designed to target CD123-positive cancer cells in patients with acute myeloid leukemia (AML), led to dose-dependent tumor growth control in a validated
Affimed Announces Acceptance of AFM24 Clinical Abstract For EGFR-wildtype (EGFRwt) Non-Small Cell Lung Cancer (NSCLC) At The 2024 Annual Meeting Of The American Society Of Clinical Oncology
Affimed Announces Acceptance of AFM24 Clinical Abstract For EGFR-wildtype (EGFRwt) Non-Small Cell Lung Cancer (NSCLC) At The 2024 Annual Meeting Of The American Society Of Clinical Oncology
Does Affimed N.V. (AFMD) Have the Potential to Rally 263.36% as Wall Street Analysts Expect?
Affimed N.V. (NASDAQ:AFMD) Q4 2023 Earnings Call Transcript
Wells Fargo Cuts Affimed Price Target to $25 From $30, Maintains Overweight Rating
Wells Fargo Cuts Affimed Price Target to $25 From $30, Maintains Overweight Rating.
Cantor Fitzgerald Reiterates Overweight on Affimed
Cantor Fitzgerald analyst Li Watsek reiterates Affimed (NASDAQ:AFMD) with a Overweight.